CCNE1 and neoplasm: INX-315 treatment resulted in tumor growth inhibition of CCNE1-amplified tumors by promoting retinoblastoma protein hypophosphorylation, inducing cell cycle arrest and delaying the onset of CDK4/6 inhibitor resistance in breast cancer (74).